Connection
Tejas Patil to Immunoconjugates
This is a "connection" page, showing publications Tejas Patil has written about Immunoconjugates.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.795 |
|
|
|
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
Score: 0.795